RGLS 8429
Alternative Names: RGLS-8429Latest Information Update: 28 Jun 2024
At a glance
- Originator Regulus Therapeutics
- Class Antisense oligonucleotides; MicroRNAs
- Mechanism of Action Gene silencing; MIRN17 microRNA expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Autosomal dominant polycystic kidney disease
Most Recent Events
- 28 Jun 2024 Regulus Therapeutics plans to request an End-of-Phase I meeting with the FDA in the fourth quarter of 2024
- 24 Jun 2024 Updated pharmacodynamics data from a phase I trial in Autosomal dominant polycystic kidney disease released by Regulus Therapeutics
- 15 Mar 2024 Updated pharmacodynamics data from a phase I trial in Autosomal dominant polycystic kidney disease released by Regulus Therapeutics